Anti-tumor activity of novel biisoquinoline derivatives against breast cancers

  • Bioorg Med Chem Lett. 2014 Oct 15;24(20):4850-3. doi: 10.1016/j.bmcl.2014.08.053.
Aruna S Jaiswal  1 ,  Dimitri Hirsch-Weil  2 ,  Erick R Proulx  2 ,  Sukwon Hong  3 ,  Satya Narayan  4
Affiliations
  • 1. Department of Anatomy and Cell Biology, University of Florida, Gainesville, FL 32610, USA.
  • 2. Department of Chemistry, University of Florida, Gainesville, FL 32611-7200, USA.
  • 3. Department of Chemistry, University of Florida, Gainesville, FL 32611-7200, USA; Research Institute for Solar and Sustainable Energies (RISE), School of Materials Science & Engineering, Gwangju Institute of Science and Technology, 123 Cheomdan-gwagiro, Buk-gu, Gwangju 500-712, Republic of Korea. Electronic address: [email protected].
  • 4. Department of Anatomy and Cell Biology, University of Florida, Gainesville, FL 32610, USA. Electronic address: [email protected].
PMID: 25240616 DOI: 10.1016/j.bmcl.2014.08.053
Abstract

Breast Cancer is classified into three groups according to its expression of hormone/growth factor receptors: (i) Estrogen receptor (ER) and Progesterone Receptor (PR)-positive; (ii) human epidermal growth factor receptor 2 (HER2)-positive; and (iii) ER, PR, and HER2-negative (triple-negative). A series of methoxy-substituted biisoquinoline compounds have been synthesized as a potential chemotherapeutic agent for the triple-negative breast cancers which are especially challenging to manage. Structure activity relationship study revealed that rigid 6,6'-dimethoxy biisoquinoline imidazolium compound (1c, DH20931) exhibited the significant growth inhibitory effects on both triple-positive and triple-negative human breast Cancer cell lines with IC50 in the range of 0.3-3.9 μM. The 1c (DH20931) is more potent than structurally related noscapine for growth inhibition of MCF7 cell line (IC50=1.3 vs 57 μM) and MDA-MB231 cell line (IC50=3.9 vs 64 μM).

Keywords
Biisoquinoline; Breast cancer; MCF7; MDA-MB231; Noscapine.
Products